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Abstract
Background: Radiation is an effective treatment against nasopharyngeal carcinoma (NPC). However,
radioresistance-induced locoregional recurrence remains as a major cause of treatment failure. Therefore, radiosensitivity
indicators prior to treatment should be developed to screen radioresistant patients. Previous studies revealed that RKIP
(Raf kinase inhibitor protein) is associated with NPC prognosis and radiosensitivity. However, the relationship of p-Ser153
RKIP (RKIP in a phosphorylated form at residue serine153) expression with the effect of radiation and prognosis of NPC
patients is not elucidated. Thus, these clinical implication of the phosphorylated RKIP in NPC has yet to be described.
Methods: The effect of p-Ser153 RKIP on locoregional relapse-free survival (LRRFS) was first analyzed in a retrospective
cohort of NPC patients without distant metastasis at initial diagnosis. They received radical intensity-modulated
radiotherapy alone. Of 180 patients were enrolled in the ongoing matched pair study. The patients were re-classified
into radioresistant group or radiosensitive group on the basis of the specified criteria. Patients in the two groups were
matched in terms of radiosensitivity-related factors. p-Ser153 RKIP was examined by immunohistochemical staining on a
NPC tissue microarray before radiotherapy. The relationship between the expression of p-Ser153 RKIP and the effect of
radiotherapy was also analyzed.
Results: In this study, a retrospective cohort with 733 cases who received radical radiotherapy alone was established.
Using the cohort, we validated that the p-Ser153 RKIP expression observed through immunohistochemical staining in a
pretreatment NPC tissue microarray was an independent prognostic factor of LRRFS and OS; we also confirmed that
endemic patients with a positive p-Ser153 RKIP expression benefited from irradiation alone in terms of locoregional
relapse-free survival. A total of 180 patients were enrolled in a matched pair study. Both groups were well matched in
terms of radiosensitivity-related factors. On the basis of the p-Ser153 RKIP expression, we predicted the following data:
80.0 % sensitivity, 73.3 % specificity, 76.7 % accuracy, 75.0 % positive predictive value, and 78.6 % negative
predictive value.
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Conclusions: Our results revealed for the first time that positive p-Ser153 RKIP expression was a favorable prognostic
factor. It was also positively correlated with the radiosensitivity of NPC. p-Ser153 RKIP could also be used as a
biomolecular marker with good availability and authenticity to preliminarily screen NPC-related clinical radiosensitivity.
Keywords: Phosphorylated Raf kinase inhibitor protein (pRKIP), Nasopharyngeal carcinoma, Radiotherapy, Sensitivity,
Prediction, Prognosis
Introduction
Radical radiation is an effective treatment against NPC;
however, locoregional recurrence remains as a major cause
of the failure of treatments for locoregionally advanced
NPC [1]. As such, local control should be enhanced to im-
prove survival and prognosis [1]. Therefore, radiosensitivity
indicators prior to treatment should be developed on the
basis of simple, reliable, and effective methods to screen
radioresistant patients. These indicators provide a reason-
able basis of specific NPC radiotherapy.
RKIP, a well-established metastasis suppressor gene, has
been identified as a negative regulator of survival signals
induced by the activation of MAPK and NF-kB pathways.
The overexpression of RKIP reverses tumor cell resistance
to apoptosis by various factors, such as irradiation [2, 3],
chemotherapeutic drugs [4, 5], and TRAIL [6]. RKIP is
also considered as a prognostic marker of several non-
head–neck cancers [7–11]. Furthermore, the RKIP protein
is associated with the metastasis, progression, and progno-
sis of NPC [12].
The functional activities of RKIP are regulated by its
phosphorylation status on serine 153 [13]. In contrast to
the unphosphorylated form, p-Ser153 RKIP (RKIP in a
phosphorylated form at residue S153) antagonizes the ac-
tions of the unphosphorylated RKIP, which inhibits survival
signals and promotes apoptosis. It is because p-Ser153
RKIP fails to effectively bind to Raf-1, p-Ser153 RKIP does
not inhibit the MAPK signaling pathway [14].
Limited data are available to explore the clinical implica-
tion of p-Ser153 RKIP in tumors. For example, the loss or
reduction of p-Ser153 RKIP expression in breast cancer
[15] is associated with poor disease-free survival; further-
more, the complete loss of p-Ser153 RKIP is an independ-
ent prognostic factor. In patients with early-stage lung
cancer or in elderly individuals, the normal expression of
phospho-RKIP is a predictive indicator of a more favor-
able survival than the reduced expression of phospho-
RKIP [16]. In contrast to these tumors, other tumors, such
as multiple myeloma (MM) and stage II colon cancer, ex-
hibit p-Ser153 RKIP that may positively contribute to the
overall cell survival and drug resistance of MM through
the constitutive activation of survival pathways and the
downstream transcription of anti-apoptotic genes [17, 18].
Considering the varied results in different tumors, we
should investigate the clinical implication of the phos-
phorylated RKIP in NPC. However, studies have yet to de-
scribe the relationship of p-Ser153 RKIP expression with
the prognosis of NPC patients and the effect of radiation
on NPC.
In this study, the effect of pre-RT p-Ser153 RKIP ex-
pression in a NPC tissue microarray on locoregional
relapse-free survival (LRRFS) was examined. The study
was based on patients from an established retrospective
cohort composed of 733 cases who received irradiation
alone. In the ongoing matched pair study, the patients
were re-classified into radioresistant group or radiosensi-
tive group on the basis of the specified criteria. This
study also determined whether p-Ser153 RKIP is closely
related to NPC radiosensitivity to investigate the predict-
ive significance of p-Ser153 RKIP as a biomarker in the
preliminary screening of the clinical response to radio-
therapy of NPC.
Materials and methods
Patients and general data
A total of 733 patients with biopsy-proven NPC from
January 2005 to December 2006 were enrolled in this
study. The patients did not manifest distant metastasis at
initial diagnosis. Patients with sufficient pretreatment
tumor biopsy specimens were initially subjected to radical
radiotherapy alone through intensity-modulated radio-
therapy (IMRT) at the Sun Yat-sen University Cancer
Center. Patient consent and approval from the Institute
Research Ethics Committee were acquired before these
clinical materials were used for research. Clinical follow-
up data were obtained from the patients’ medical records.
A patient was considered eligible for this study if the
following criteria were satisfied before treatment was ad-
ministered: (1) histologically confirmed non-keratinizing
or undifferentiated NPC (World Health Organization
[WHO] type II or type III cancer); (2) Stage I to Stage
IV(A–B) according to the International Union Against
Cancer (UICC) TNM classification (2002); (3) perform-
ance status ranging from 0 to 2 in accordance with the
Eastern Cooperative Oncology Group system; (4) absence
of serious renal dysfunction, as demonstrated by serum
creatinine of <1.5 mg/dL and a creatinine clearance rate
of at least 60 mL/min; (5) absence of serious liver
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dysfunction, as demonstrated by bilirubin level of
<1.5 mg/dL, with a ratio of aspartate aminotransferase
to alanine aminotransferase of < twofold the normal
upper limit; and (6) adequate hematologic function,
as demonstrated by a hemoglobin concentration of
≥100 g/L, a leukocyte count of ≥4.0 × 109/L, and a
platelet count of ≥100 × 109/L.
Patients were excluded from this study on the basis of
the following criteria: (1) pathology types that were not
WHO II/III NPC; (2) distant metastasis under clinical
examination, imaging, or biopsy proven; (3) with any
form of chemotherapy; (4) previous radiation therapy to
the head and/or neck region; (5) previous surgery on the
primary tumor site or neck with the exception of diag-
nostic biopsy; (6) history of malignant tumors or mul-
tiple tumors occurring at the same time; and (7) disease
occurring during pregnancy.
Reclassification of patients into the radioresistant group or
the radiosensitive group according to the following criteria
The enrolled patients did not receive treatment against
disease prior to biopsy, with a minimum follow-up of
5 years following the beginning of radiotherapy. The pa-
tients were classified into two groups according to the
following criteria. Patients with biopsy-proven recurrent
NPC occurring at the original anatomical site of the
nasopharynx and/or the neck within 5 years of a radio-
therapy course were classified as the radioresistant
group. The pathological type at relapse was the same as
the previous type before treatment. Patients with a mini-
mum follow-up of 5 years following the beginning of
radiotherapy, without evidence of recurrence both at the
original site of the tumor and at the neck by routine
check-ups, including MRI or CT, were classified as the
radiosensitive group. To reduce confounding variables of
the radiosensitive and radioresistant groups, we ensured
that the patients in the two groups were well matched in
terms of the factors closely correlated with radiosensitiv-
ity, that is, T stage, TNM, N stage, histological grade,
gender, average age, radiation dose to the nasopharynx
and the neck, and pretreatment hemoglobin between the
two groups were not different statistically (Table 3).
Tumors were staged according to the UICC 2002 cancer
staging classification.
p-Ser153 RKIP was examined by immunohistochemi-
cal staining method in 90 radiosensitive and 90 radiore-
sistant NPC tissues from enrolled patients before
radiotherapy. The relationship between the rate and ex-
tent of p-Ser153 RKIP expression and the effect of
radiotherapy was analyzed.
Patient treatment
All enrolled patients received radical irradiation alone
with intensity-modulated radiotherapy. Nasopharyngeal
gross tumor volume (GTVnx) and the gross tumor vol-
ume of positive neck lymph nodes (GTVnd) included all
gross diseases visualized on imaging examinations, such
as CT and/or MRI. CTV-1 was defined as the high-risk
clinical target volume that includes GTVnx plus a mar-
gin of 5 mm to 10 mm and the entire nasopharyngeal
mucosa plus 5 mm submucosal volume. CTV-2 was de-
signed for potentially involved regions. The regions not
only included the posterior part of nasal cavity, posterior
wall of sinus maxillaris, anterior third of clivus and cer-
vical vertebra, and skull base; the region also included
parapharyngeal space, pterygopalatine fossa, posterior
ethmoid sinus, inferior sphenoid sinus, and cavernous
sinus, as well. CTV-2 also included the retropharyngeal
lymph nodal regions from the cranial base to lower edge
of the second cervical vertebra. The CTV of the neck
nodal regions (CTV-nd) included levels II, III, IV, and V,
which were contoured according to the recommended
principle by RTOG CTV delineation protocol for head
and neck malignancies [19].
The planning target volume (PTV) was obtained
based on each volume with an additional 3 mm margin
and considering setup variability. Critical normal struc-
tures, which include not only the spinal cord, brainstem,
optic nerves, optic decussation, lens, and eyeballs but
also lobi temporalis, pituitary gland, temporomandibu-
lar joints, mandibular bone, and parotid glands, were
contoured and set as organs at risk (OARs) during
optimization of a treatment plan. The radiation doses
prescribed in the protocol was as follows: a total dose of
68 Gy in 30 fractions at 2.27 Gy per fraction to the PTV
of GTVnx, 60 Gy to 66 Gy to the PTV of the GTVnd
for positive cervical lymph nodes in 30 fractions, 60 Gy
at 2 Gy per fraction to the PTV of CTV-1, and 54 Gy at
1.8 Gy per fraction to the PTV of CTV-2. All patients
were treated with one fraction daily for 5 days each
week. The dose received by each OAR should be less
than its maximum tolerance limit according to the
RTOG 0225 protocol.
Tissue microarray construction
A tissue microarray (TMA) was constructed with arch-
ival formalin-fixed, paraffin embedded tissues from 733
primary NPC and 49 normal nasopharyngeal epithelial
tissue (NNET) samples. NNET samples were obtained
from patients with biopsy-proven inflammatory diseases.
First, after a pathologist reviewed the slides stained with
hematoxylin and eosin and the localized tumor/normal
areas, a tissue core from the donor block was punched by
using a hollow needle with an inner diameter of 1.5 mm.
Then, samples from each tissue were precisely arrayed in
a recipient block at specifically assigned locations. TMA
blocks were sliced into 4 μm sections embedded in slides
for immunohistochemical (IHC) staining.
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Immunohistochemical staining of tissue microarray
The p-Ser153 RKIP expression levels were checked by
using a semi-quantitative IHC assay. TMA staining was
performed with an avidin biotin procedure following
manufacturer's kit instructions by using standard two-
step indirect immunohistochemistry, which is similar to
that in previously described experiments [16]. The pri-
mary antibody used was a rabbit anti-human p-Ser153
RKIP monoclonal IgG (clone number, EP2845Y, rabbit
anti-human, ab75971, USA) at 1:250 dilution. We used
positive controls, which consisted of lung cancer sam-
ples that were previously exhibited to be stained with
this antibody [15]. Tris-buffered saline in place of the
primary antibody was used as a negative control.
Evaluation of immunohistochemical staining
Similarly in previously described experiments [12], stain-
ing intensity for each section was scored by using the
following scale: no staining as 0 points, mild staining as
1 point, moderate staining as 2 points, and intense stain-
ing as 3 points. A positively stained proportion was
scored using the following scale: 1 point for 1 % to 24 %,
2 points for 25 % to 49 %, 3 points for 50 % to 74 %, and
4 points for 75 % to 100 %. The intensity and proportion
of the ten fields-of-view were first averaged, respectively,
prior to scoring. The final score was obtained by multi-
plying the two scores, thus forming a scale of 0, 1, 2, 3,
4, 6, 8, 9, and 12 points. 0 ~ 1 point was defined as (−),
2 ~ 4 points as (+), 6 ~ 8 points as (++), and 9 ~ 12
points as (+++). Two independent histopathologists
were assigned to conduct the scoring. The histopatholo-
gists were blinded to the clinicopathological characteris-
tics, including the received treatment and treatment
outcome, of all patients.
Statistical analysis
Our observations ended on December 31, 2012. The pri-
mary endpoint of the current study was LRRFS. The sec-
ondary endpoints were progression-free survival (PFS)
and overall survival (OS). The duration of time to locor-
egional relapse was measured from the date of the start
of radiotherapy until documented treatment failure. PFS
was assessed from the start of treatment to the first de-
fined event of failure, i.e., locoregional relapse and/or
distant metastasis in patients who completely responded
to radiation therapy, as well as the definite progression
of disease in patients who partially responded. The dur-
ation of overall survival was calculated from the start of
radiation therapy until death from any cause or until the
date of the last follow-up visit for patients still alive.
These endpoints were analyzed and compared using the
Kaplan-Meier method and log-rank test. Multivariate
analyses with the Cox proportional hazards regression
model were used to determine the prognostic value of
p-Ser153 RKIP expression.
The comparison of each matched factor between pa-
tients in the two groups was assessed by Pearson’s chi-
square test or Students’ test. The differences in the two
groups in terms of positive p-Ser153 RKIP expression of
rate and extent were assessed by Pearson’s chi-square test
or Fisher’s exact test. The correlation between p-Ser153
RKIP protein expression and the response to radio-
therapy was analyzed by Spearman’s rank correlation




The median follow-up duration was 63 months (range,
4 months to 84 months) for all patients and 84 months
(range, 10 months to 84 months) for the surviving pa-
tients. The one-year, three-year, and five-year follow-up
rates were 97.2 %, 96.3 %, and 92.7 %, respectively. Dur-
ing the follow-up period, a total of 155 patients devel-
oped locoregional recurrence, and the locoregional
recurrence rate was 21.11 % (155/733). Original data can
be acquired in the Additional file 1.
p-Ser153 RKIP expression in NNET and primary NPC
tissues
The IHC staining results revealed that strongly positive
p-Ser153 RKIP staining was observed in the cytoplasm
of NPC tumor cells for 80.0 % (72/90) of patients in the
radiosensitive group (Fig. 1a and d) and NNET (Fig. 1c
and f ); by contrast, negative p-Ser153 RKIP staining
was observed for 73.3 % (72/90) of patients in the
radioresistant group (Fig. 1b and e). Of the 733 en-
rolled patients, 391 (53.3 %) showed positive p-Ser153
RKIP expression. The correlation of p-Ser153 RKIP
expression with clinical characteristical factors was
shown in Table 1.
Effect of p-Ser153 RKIP expression on survival for all of
the enrolled patients
The five-year OS rates were 76.1 % and 44.1 % for
the p-Ser153 RKIP positive-expression group and the
p-Ser153 RKIP negative-expression group, respectively.
The difference between the two groups in terms of five-
year OS was significant on the basis of log-rank test (p <
0.001, Fig. 2a). We also analyzed the five-year LRRFS,
DMFS, and PFS of the patients in the p-Ser153 RKIP
positive-expression group and the p-Ser153 RKIP negative-
expression group. The five-year LRRFS were 85.3 % and
66.5 % (p < 0.01, Fig. 2b) in the two groups, respectively.
Likewise, a significant difference between the two groups
was observed in terms of five-year DMFS (75.1 % versus
57.2 %, p = 0.023, Fig. 2c). Similarly, the five-year PFS
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were 69.3 % and 38.8 % (p < 0.01, Fig. 2d) in the two
groups, respectively
In addition to irradiation dose to the neck or the pri-
mary nasopharyngeal site, sex, age, TNM stage, T stage,
N stage, and p-Ser153 RKIP expression were further in-
troduced to the Cox regression model by using the Enter
method. The results revealed that positive p-Ser153
RKIP expression was an independent prognostic factor
of LRRFS (HR = 0.133, CI = 0.034-0.530, p = 0.004) and
OS (HR = 0.226, CI = 0.118-0.432, p <0.01) in Table 2.
And it was also an independent prognostic factor of
PFS (HR = 0.249, CI = 0.125-0.493, p <0.01) and DMFS
(HR = 0.093, CI = 0.025-0.346, p <0.01).
The matched pair comparison of clinical characteristics
between the radiosensitive group and radioresistant
groups
As is shown in Table 3, most of the well-known factors
that influence NPC radiosensitivity between the radio-
sensitive group and the radioresistant group were well-
balanced in the current study. These factors included
clinical staging, radiation dose, anemia, tumor differenti-
ation degree, and certain other factors.
Relationship between p-Ser153 RKIP expression and
radiation response
The positive rate of p-Ser153 RKIP expression in the radio-
sensitive group versus the radioresistant group was 80.0 %
versus 26.7 %. The rates of the positive p-Ser153 RKIP ex-
pression in primary NPC significantly differed between the
groups (χ2 = 51.429, p < 0.01; Table 4). The staining scores
of the p-Ser153 RKIP expression were significantly differ-
ent between the two groups (χ2 = 12.498, p < 0.01, Table 4).
Spearman analysis revealed that the intensity and rate of
the the p-Ser153 RKIP protein expression was negatively
correlated with the radioresistance of NPC (r = −0.344,
r = −0.535, respectively, p < 0.01 for both groups).
p-Ser153 RKIP discrimination of NPC response to
radiation
Based on the expression of p-Ser153 RKIP as a marker pre-
dicting radio-resistance, sensitivity, specificity, accuracy,
positive predictive value, and negative predictive value were
80 % (72/90), 73.3 (66/90), 76.7 % [(72 + 66)/180], 75 %
(72/96), and 78.6 % (66/84), respectively. The false positive
and false negative rates were predicted as 26.7 % (24/90)
and 20.0 % (18/90), respectively.
Discussion
Limited data are available to investigate the clinical im-
plication of the phosphorylated RKIP in tumors [15–18].
However, the relationship of p-Ser153 RKIP expression
with the effect of radiation and prognosis of NPC pa-
tients has yet to be described. Thus, we should explore
the clinical implication of the phosphorylated RKIP in
NPC. In this study, we found for the first time that posi-
tive p-Ser153 RKIP was a favorable prognostic factor for
patients who received radiation alone and that the en-
demic NPC patients with positive p-Ser153 RKIP expres-
sion in a NPC tissue microarray before treatment
benefited from irradiation alone in terms of LRRFS. This
validation was based on the patients from an estab-
lished retrospective cohort composed of 733 cases. In
the ongoing matched pair study and through detec-
tion by using simple IHC staining, p-Ser153 RKIP
was positively correlated with radiosensitivity to NPC.
Moreover, we found that p-Ser153 RKIP could be
used as a biomolecular marker with good availability
Fig. 1 Immunohistochemical staining of p-Ser153 RKIP expression in NNET and primary NPC tissues. a, d Strongly and positively stained representative
in primary NPC tumors in the radiosensitive group (100×). b, e Weakly and positively stained representative in primary NPC tumors in the radioresistant
group (100×). c, f Strongly and positively stained representative in NNET (100×)
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and authenticity to preliminarily screen the clinical radio-
sensitivity of NPC.
NPC is one of the most common malignancies in
South China. In general, NPC is highly radiosensitive,
and radical radiation is one of the most effective treat-
ment methods against NPC. IMRT is a major break-
through in the treatment of NPC. IMRT can be applied
to improve tumor control. Encouraging results of NPC
treated with IMRT have been reported. However, NPC
patients with T3 or T4 stage disease showed a five-year
relapse rate of 12.3 %–28.2 %, even with advanced IMRT
[20, 21]. Similarly, several patients with early stages of
disease develop early recurrence even with a sufficient
radiation dose. Local control probability can vary among
patients with NPC with the same staging, radiation dose,
and differentiation grade of tumor. This finding indicates
the presence of a radiosensitivity determinant. On the
other hand, how to find the radiosensitivity predictors
by precise, rapid, and economical methods is also a
challenge. Some methods can be used to detect intrinsic
radiosensitivity. However, they were complex, time-
wasting. Precise, rapid, and economical methods used to
predict intrinsic radiosensitivity are insufficient. There-
fore, the exploration of numerous novel methods are
currently underway.
Li and his colleagues [22] found that tumor recurrence
time after radiotherapy can be used to evaluate radiosen-
sitivity, which possessed a certain value in clinical prac-
tice. However, this method according to recurrence time
alone after finishing radiation can only indirectly indi-
cate radiosensitivity. Moreover, this method could be in-
terfered by several clinopathological factors influencing
radiation outcome, such as clinical staging, radiation
dose, anemia, differentiation grade of tumor and so on.
Therefore, in the settings, radiosensitivity cannot be pre-
cisely predicted.
As is known to us, intrinsic radiosensitivity determin-
ant in NPC is a functional gene and/or its expressing
protein, which bear certain connection with the prolifer-
ation and/or apoptosis of cancer cells. Several studies on
intrinsic radiosensitivity at the molecular level can ac-
curately reflect radiosensitivity against cancer. Therefore,
an increasing number of oncologists have attached im-
portance to these radiosensitivity determinants.
RKIP, a well-established metastasis suppressor, has
been identified as a negative regulator of survival signals.
RKIP is shown to be a prognostic marker in the patho-
genesis of several non-head–neck cancers [7–11]. In
NPC, Ruan and our previous studies had revealed that
RKIP protein was not only associated with the progres-
sion and prognosis of NPC but also to NPC radiosensi-
tivity [3, 12]. Patients with radioresistant NPC presented
different RKIP expression levels from those with radio-
sensitive tumor. The overexpression of RKIP reverses
tumor cell resistance to apoptosis by various factors,
such as irradiation [2, 3], chemotherapeutic drugs [4, 5],
and TRAIL [6].
However, the effect of p-RKIP expression on prognosis
of NPC has yet to be elucidated. The inhibitory activity of
RKIP on the Raf-1/MEK/ERK pathway is partially regu-
lated by PKC-induced phosphorylation of RKIP at serine
153 [13]. Therefore, we hypothesized that the phosphory-
lated form of RKIP at the S153 residue (p-Ser153 RKIP)
may be related to NPC prognosis. Previous reports showed
Table 1 The correlation of p-Ser153 RKIP expression with clinical
characteristical factors
Characteristic Total p-Ser153 RKIP expression
(n = 733) Negative Positive P value
No. % No. % No. %
Age, y(median)
≤46 362 49.39 164 45.3 198 54.7 0.468
>46 371 50.61 178 48.0 193 52.0
Sex
Male 394 53.75 168 42.6 226 57.4 0.019
Female 339 46.25 174 51.3 165 487
N classification
N0+1 377 51.43 174 46.2 203 53.8 0.778
N2+3 356 48.57 168 47.2 188 52.8
T classification
T1+2 438 59.75 188 42.9 250 57.1 0.014
T3+4 295 40.25 154 52.2 141 47.8
TNM classification
I + II 335 57.57 160 47.8 175 52.2 0.583
III + IVa + b 398 42.43 182 45.7 216 54.3
Pathologic classification
Type I 10 1.36 4 40 6 60 0.116
Type II 84 11.32 48 57.1 36 42.9
Type III 639 87.31 290 45.4 349 54.6
Survival status
Yes 415 56.62 130 31.3 285 68.7 <0.001
No 318 43.38 212 66.7 106 33.3
Local-regional relapse
Yes 155 21.15 92 59.4 63 40.6 0.001
No 578 78.85 250 43.3 328 56.7
Post-treatment progression
Yes 324 44.20 197 60.8 127 39.2 <0.001
No 409 56.80 145 35.5 264 64.5
Post-treatment distant metastasis
Yes 224 30.56 125 55.8 99 44.2 0.001
No 509 69.44 217 42.6 292 57.4
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that p-Ser153 RKIP dissociates RKIP from Raf-1, reversing
the inhibitory function [13, 14]. Moreover, p-RKIP binds to
G protein–coupled receptor kinase-2 (GRK-2) and dissoci-
ates it from G protein–coupled receptors (GPCRs), thus
inhibiting GRK-2-mediated phosphorylation of GPCRs.
This inhibition further prevents both receptor internaliza-
tion and inactivation, as well as promotes cell growth and
survival [14]. These results provide several theoretically
convincing evidences to support the concept that p-Ser153
RKIP may be recognized as a positive regulator of survival
signals, in contrast to RKIP. Interestingly, our present data
do not agree with these findings. In other words, positive
p-Ser153 RKIP expression is a strong predictor of favorable
outcome. Relatively higher levels of p-Ser153 RKIP could
predict better survival in comparison with relatively lower
expression. Similarly, our findings are in agreement with
the functional activities of p-Ser153 RKIP in breast cancer
and lung cancer [15, 16]. In several other tumors, such as
MM and stage II colon cancer, p-Ser153 RKIP may con-
tribute positively to overall cell survival and drug resistance
[17, 18]. The prognostic differences of p-Ser153 RKIP in
different tumors is worth further study.
Previous studies have shown that a high or positive
RKIP expression is related to the favorable prognosis in
endemic-NPC [7–12]. We demonstrated that a positive
p-Ser153 RKIP expression is also related to the favorable
prognosis in the current study. As a possible antagonist
of RKIP [13, 14], why does p-Ser153 RKIP expression
also result in the beneficial outcomes, which is similar to
RKIP? There is no definite explain for the findings.
Firstly, Sam Cross-Knorr [18] reported that nuclear
p-Ser153 RKIP-high expression is associated with poor
prognosis whereas cytoplasmic p-Ser153 RKIP-high expres-
sion is associated with better prognosis in stage II colon
cancer patients, which indicates that p-Ser153 RKIP might
play a quite different role from cytoplasm to nuclei. So we
speculate that good prognostic implications of p-Ser153
RKIP in our current study may be associated with its ex-
pression in cytoplasm but not in nuclei in NPC. Since the
majority of studies[7–11] including our previous studies[12]
showed the staining of RKIP positive NPC samples was in
cytoplasm but not in nuclei, we furtherly speculate a
dominant proportion of RKIP expression may be in the p-
Ser153 RKIP form. Secondly, Al-Mulla F et al. [16] also
found that both RKIP and p-Ser153 RKIP are related to
the favorable prognosis in a study on ductal breast cancer,
which is similar to our results. All these data demon-
strated it is not impossible that both RKIP and p-Ser153
RKIP are related to the favorable prognosis in NPC.
The relationship between p-RKIP expression levels
and radiosensitivity to NPC has yet to be reported. In
the present study, we found a differential expression of
p-Ser153 RKIP protein between the radiosensitive group
and the radioresistant group. More importantly, we
Fig. 2 Kaplan–Meier survival curve of NPC patients on the basis of the p-Ser153 RKIP expression levels of a OS; b LRRFS; c PFS; and d DMFS
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further validated that pretreatment positive p-Ser153
RKIP expression levels are positively associated with
NPC radiosensitivity (r = 0.535, p < 0.01). This finding is
similar to the function of RKIP in terms of NPC radio-
sensitivity [3].
p-RKIP expression status has yet to be reported as an
indicator of preliminarily screening radiosensitivity to
NPC. We found that p-Ser153 RKIP expression can logic-
ally predict radiosensitivity of NPC using p-Ser153 RKIP
as a maker. Sensitivity, specificity, accuracy, positive pre-
dictive value, and negative predictive value were predicted
as 80.0 %, 73.3 %, 76.7 %, 75.0 %, and 87.6 %, respectively,
all amounting to 73.0 %. Liu et al. [23] found that COX-2
expression is a good predictor of NPC radiosensitivity,
with good sensitivity of 86.67 %, specificity of 63.3 %, ac-
curacy of 75.0 %, positive predictive value of 70.27 %, and
negative predictive value of 82.6 %. Contrastingly, in the
current study, specificity of 73.3 %, accuracy of 76.7 %,
and positive predictive value are superior to those in pre-
vious results, but sensitivity and negative predictive value
are poorer. The used method, IHC staining on a NPC tis-
sue microarray, is more simple and practical. We conclude
that p-Ser153 RKIP-positive expression could serve as a
biomarker in the preliminarily screening of the intrinsic
radiosensitivity of NPC.
The retrospective study matched the same period. In
the study, most main factors influencing radiosensitivity,
i.e., clinical staging, radiation dose, anemia, tumor differ-
entiation degree, and certain other factors between two
matched groups were well-balanced to the maximum ex-
tent. Our objective is to balance the factors that interfere
with intrinsic radiosensitivity between two groups. Thus,
Table 2 Matched pair comparison of clinical characteristics between the radiosensitive group and the radioresistant group.
Multivariate analysis of Cox proportional hazards model for 5-year LRRFS, OS, PFS, and DMFS (n = 733)
Endpoints Prognostic factors HR 95.0 % CI p value
LRRFS p-Ser153 RKIP expression(positive versus negative) 0.133 0.034-0.530 0.004
TNM classification(I + II versus III + IVA+B) 0.310 0.092-1.047 0.059
N classification (N0+1 versus N2+3) 0.276 0.112-0.677 0.005
T classification (T3+4 versus T1+2) 3.594 1.199-10.779 0.022
Sex (female versus male) 0.144 0.023-0.878 0.056
Age (<46 year versus ≥46 year) 1.075 0.992-1.164 0.077
Absolute irradiation dose to neck (Gy) 0.347 0.097-0.910 0.066
Absolute irradiation dose to primary nasopharyngeal site(Gy) 0.211 0.079-0.563 0.062
OS p-Ser153 RKIP expression(positive versus negative) 0.226 0.118-0.432 <0.01
N classification(N0+1 versus N2+3) 0.196 0.055-0.441 0.085
T classification(T3+4 versus T1+2) 2.525 1.083-5.888 0.032
Sex (female versus male) 1.132 1.003-1.362 0.191
Age(<46 versus ≥ 46) 1.032 1.003-1.062 0.271
TNM classification (I + II versus III + IVA+B) 0.310 0.092-1.047 0.059
DMFS p-Ser153 RKIP expression(positive versus negative) 0.093 0.025-0.346 <0.01
N classification(N0+1 versus N2+3) 0.122 0.048-0.425 0.010
T classification (T3+4 versus T1+2) 8.656 1.037-72.232 0.046
Sex (female versus male) 1.032 1.002-1.326 0.121
Age(<46 versus ≥ 46) 1.012 1.013-1.072 0.371
TNM classification (I + II versus III + IVA+B) 0.310 0.092-1.047 0.049
PFS p-Ser153 RKIP expression(positive versus negative) 0.249 0.125-0.493 <0.01
N classification(N0+1 versus N2+3) 0.226 0.118-0.432 <0.01
Sex (female versus male) 2.886 0.987-8.439 0.053
T classification (T3+4 versus T1+2) 3.525 1.083-6.27 0.032
Age(<46 versus ≥ 46) 1.032 1.003-1.262 0.318
Absolute irradiation dose to neck (Gy) 0.747 0.497-1.100 0.066
Absolute irradiation dose to primary nasopharyngeal site(Gy) 0.411 0.079-0.763 0.062
Abbreviations: p-Ser153 RKIP RKIP in phosphorylated form at residue serine153, RKIP Raf kinase inhibitory protein, HR hazard ratio, CI confidence interval,
PFS progression-free survival, OS overall survival, DMFS distant metastasis-free survival, LRRFS locoregional relapse-free survival
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a difference between two matched groups should be
consistent with intrinsic radiosensitivity, as anticipated.
Therefore, our study results must be authentic.
Most of patients with negative p-Ser153 RKIP ex-
pression are radio-resistant in the current study. These
patients showed inferior effectiveness when radiation
alone is given, presenting a relapse rate of about 30.0 %
within five years. If a more aggressive treatment is com-
bined with chemotherapy, molecular targeted therapy,
and immunotherapy from the beginning of treatment,
five-year survival may be improved.
In the previous study, RKIP can inhibit the radiation
resistance of cancer caused by Raf-1[24]. RKIP activity
was found to be under the control of post-translational
modification, which involves PKC-mediated phosphoryl-
ation at serine 153 [13]. In the current study, pretreat-
ment positive p-Ser153 RKIP expression levels showed
negative correlation with radio-resistance to NPC and
could serve as a biomarker in the preliminary screening
of the intrinsic radiosensitivity of NPC. Therefore, we
speculate that any available means that regulate the
post-translational modification of RKIP at serine 153
may be a target for therapeutic intervention. For ex-
ample, p-Ser153 RKIP-inductive agents and/or PKC-
regulators may partially enhance tumor radiosensitivity
and improve clinical outcome.
Our concurrent research found that p-Ser153 RKIP
protein expression can act as an effective maker for use
in radiosensitivity prediction with higher sensitivity.
However, the false positive rate of 26.7 % is still high as
a predictor. This single marker in predicting radiosensi-
tivity remains to be improved. Therefore, we should
Table 3 Multivariate analysis of the five-year Cox proportional hazard model of LRRFS; OS; DMFS; and PFS. The matched pair
comparison of clinical characteristics between the radiosensitive group (n = 90) and radioresistant group (n = 90)
Items Radiosensitive group Radioresistant group P












WHO Classification I (cases) 12 14 >0.05
II(cases) 24 28
III(cases) 54 48
Sex Man(cases) 49 55 >0.05
Female(cases) 41 35
Age (x  s)(cases) 44.5 ± 14 49.0 ± 12 >0.05
Preatment Hemoglobin(g/L) (x  s) 138.5 ± 13.2 135.8 ± 15.5 >0.05
Total irradiation dose of primary nasopharyngeal carcinoma (Gy) (x  s) 72.5 ± 4.2 72.6 ± 3.8 >0.05
Total irradiation dose of positive neck lymph node (Gy) (x  s) 62.2 ± 2.3 64.5 ± 4.2 >0.05
Preventive irradiation dose of negative neck lymph node (Gy) (x  s) 54.2 ± 3.3 53.5 ± 4.3 >0.05
Table 4 The Expression of the p-Ser153 RKIP protein in the




group (n = 90)
The radiosensitive




- 66 18 84 P* < 0.01
+ 11 10 21 P** < 0.01
++ 8 24 32
+++ 5 38 43
Abbreviations: RKIP Raf kinase inhibitory protein, p-Ser153 RKIP RKIP in
phosphorylated form at residue serine153, Ser serine
Note: P*, the p-Ser153 RKIP-positive expression versus the p-Ser153 RKIP–negative
expression; P**, the comparison among 3 different staining scores of the
p-Ser153 RKIP-positive expression
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explore more predictors of radiosensitivity. Moreover,
we confirm that sensitivity and/or specificity could be
improved when p-Ser153 RKIP is combined with other
indicators.
Conclusions
In conclusion, using a NPC tissue microarray with
immunohistochemistry staining, we found for the first
time that positive p-Ser153 RKIP was favorable prognos-
tic factor for patients who received radiation alone and
also positively correlated with NPC radiosensitivity. The
expression could be used as a biomolecular marker with
good availability and authenticity to preliminarily screen
the internal radiosensitivity of NPC.
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